We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medical Mktg | LSE:MMG | London | Ordinary Share | GB0004150685 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 6749D
Medical Marketing Int'l Group PLC
17 September 2008
Results of Annual General Meeting
Wednesday 17 September 2008 - Medical Marketing International Group plc ("MMI" or the "Company") (AIM:MMG), the life sciences company
focused on the development of drugs for cancer, confirms that at its Annual General Meeting of shareholders held today resolutions 1 to 6,
being ordinary resolutions, were passed. In respect of resolutions 7-10, being special resolutions, the results of a poll on these
resolutions and the Annual General Meeting were adjourned to 10.30am on Wednesday 17 December 2008 at the offices of J.M. Finn & Co, 4
Coleman Street, London, EC2R 5TA.
As part of general cost efficiency, the Company also announces that Rob Sprawson, Chief Financial Officer, has, in agreement with
Eversecretary Limited, replaced Eversecretary Limited as the Company Secretary with immediate effect. Eversheds LLP remain the Company's
principal legal advisers.
Enquiries:
Medical Marketing International Group plc
Phil Cartmell, Non-executive Chairman Tel: +44 (0) 1223 477 677
Mark Burton, Chief Technical Officer
Rob Sprawson, Chief Financial Officer
FinnCap
Sam Smith/Charlie Cunningham Tel: +44 (0)20 7600 1658
Financial Dynamics
David Yates/Emma Thompson Tel: +44 (0)20 7831 3113
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class
compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug
candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.
Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any
notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication
shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI
electronically shall not apply to MMI.
-ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSFSFLWSASEFU
1 Year Medical Mktg Chart |
1 Month Medical Mktg Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
